How GPR75 affects obesity-linked heart and metabolism problems
GPR75 in obesity-driven cardiovascular and metabolic complications
This project looks at whether targeting the protein GPR75 could help prevent heart and metabolism problems in people with obesity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Medical College NIH-funded |
| Lab location | 1 site (Valhalla, United States) |
| Project ID | NIH-11294176 on NIH RePORTER |
What this research studies
Researchers will study how a lipid called 20-HETE binds to the receptor GPR75 in fat cells and blood vessel cells and triggers inflammation, insulin resistance, and blood-vessel dysfunction. The team will use laboratory experiments in cells and animal models and analyze tissues relevant to obesity to map the cellular steps involved. They will focus on effects in the endothelium and adipose tissue, including changes in eNOS signaling, ACE expression, NF-κB activation, adipocyte size, insulin signaling, glucose handling, and mitochondrial function. The goal is to identify points in this pathway that could be blocked to reduce obesity-driven metabolic and cardiovascular harm.
Who could benefit from this research
Good fit: People living with obesity, insulin resistance, type 2 diabetes, or obesity-related high blood pressure would be the most likely to benefit from therapies arising from this research.
Not a fit: People without obesity-related metabolic or cardiovascular conditions, or whose illness is due to unrelated rare genetic causes, are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could point to new drug targets that prevent or reduce obesity-related high blood pressure, diabetes, and heart disease.
How similar studies have performed: Prior laboratory and animal studies have already linked 20-HETE and GPR75 to blood pressure and metabolic problems, but human therapies based on this pathway remain unproven.
Where this research is happening
Valhalla, United States
- New York Medical College — Valhalla, United States (Active)
Researchers
- Principal investigator: Schwartzman, Michal Laniado — New York Medical College
- Study coordinator: Schwartzman, Michal Laniado
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.